Compare AVXL & PUSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVXL | PUSA |
|---|---|---|
| Founded | 2004 | 2023 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.9M | 101.2M |
| IPO Year | 2013 | 2024 |
| Metric | AVXL | PUSA |
|---|---|---|
| Price | $1.26 | $1.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.25 |
| AVG Volume (30 Days) | ★ 1.2M | 913.1K |
| Earning Date | 11-24-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $2,964,377.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $301.76 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.13 | $1.61 |
| 52 Week High | $7.60 | $4.45 |
| Indicator | AVXL | PUSA |
|---|---|---|
| Relative Strength Index (RSI) | 27.79 | 27.88 |
| Support Level | $1.14 | N/A |
| Resistance Level | $1.60 | $3.95 |
| Average True Range (ATR) | 0.10 | 0.18 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 14.89 | 14.06 |
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
Aureus Greenway Holdings Inc own and operate two public golf country clubs in Florida. The golf country clubs include two golf-courses with over 13,000 yards of combined fairways, clubhouses boasting food and beverage options, aquatic golf ranges, and pro shops to assist any level of golfer and also host local golf leagues, golf-tournaments, and private events. Its golf country clubs is organized into four principal business segments: (i) golf recreation, retail golf products, and equipment and facilities rental, (ii) membership dues, (iii) food and beverage services. and (iv) ancillary services and amenities. All assets of the Company are located in Florida and all revenue is generated from Florida.